CXCL9 and non-small cell lung carcinoma: ,44,45,46,47 In this report, we demonstrate that in situ vaccination with CXCL9/10-DC elicits antitumor responses in multiple murine models of NSCLC and enhances the efficacy of PD-1/PD-L1 blockade.